Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography–electrospray mass spectrometry for therapeutic drug monitoring

Ansermot, Nicolas; Brawand-Amey, Marlyse; Eap, Chin B.

doi:10.1016/j.jchromb.2011.12.028

Cited by 43 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method showed acceptable repeatability (CV 1.6–4.3%) and intermediate precision (CV 3.7–8.2%). The lower limit of quantification of citalopram was 1 ng/mL …”

Section: Methodsmentioning

confidence: 99%

Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment

Courlet

Guidi

Glatard

et al. 2019

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Aims The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug–drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen. Methods A population pharmacokinetic analysis was performed using NONMEM. A total of 159 plasma concentration measurements were obtained from 39 human immunodeficiency virus (HIV)‐infected and 71 uninfected psychiatric patients. The influence of age, weight, sex, HIV and psychiatric cohorts, racemic citalopram treatment, and comedications on oral clearance was examined. Simulations served to calculate the percentage of patients expected to be under‐ or over‐exposed, considering established therapeutic targets (15–80 ng/mL). Results A 1‐compartment model with first‐order absorption and elimination described the data adequately. The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively. Escitalopram disposition did not differ between HIV‐infected and uninfected patients, and was not affected by antiretroviral treatments. Coadministration of at least 1 proton‐pump inhibitor (CYP2C19 inhibitor) modestly influenced escitalopram elimination (clearance decreased by 19%), with limited clinical relevance. Model‐based simulations showed that, under a standard regimen of 10 mg once daily, a significant proportion of patients (56%) might be under‐exposed. Conclusion The variability in escitalopram disposition is large and poorly explained by demographic, clinical and environmental covariates, thus suggesting a role for dosage individualization based on therapeutic drug monitoring in case of poor clinical response. Escitalopram disposition is modestly impacted by comedications and therefore no a priori dosage adjustments are needed in patients receiving antiretroviral treatments, including boosted regimens.

show abstract

“…The method showed acceptable repeatability (CV 1.6–4.3%) and intermediate precision (CV 3.7–8.2%). The lower limit of quantification of citalopram was 1 ng/mL …”

Section: Methodsmentioning

confidence: 99%

Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment

Courlet

Guidi

Glatard

et al. 2019

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…A blood drawing was performed before each session (i.e., 3–4 hr after ingestion of escitalopram). Serum concentrations of escitalopram were measured by liquid chromatography/mass spectrometry as previously described (Ansermot, Brawand‐Amey, & Eap, ). CYP2C19 genotypes (analysis of *2 (rs4244285), *3 (rs4986893), and *17 (rs12248560) alleles) and ABCB1 genotypes (analysis of G2677T (rs1045642) and C3435T (rs2032582) alleles) were determined as previously described (Crettol et al., ).…”

Section: Methodsmentioning

confidence: 99%

The effect of a single dose of escitalopram on sensorimotor networks

et al. 2018

Self Cite

View full text Add to dashboard Cite

IntroductionServing as a pilot study of poststroke pharmacotherapy, the present investigation was intended to establish the effect of a single dose of escitalopram on motor task performance in normal volunteers.MethodsTen healthy volunteers of median age 63 years including four females performed a well‐studied tactile manipulation task in two fMRI sessions using a double‐blind cross‐over design. The sessions began approximately three hours after ingestion of 20 mg escitalopram or placebo presented in pseudorandom order. The fMRI image sequences were submitted to principal component analysis (PCA).ResultsBased on volume correlations of task‐related principal components with the mean component images derived in our previous study, we established the reproducibility of two networks of sensorimotor activity proposed there. The network reflecting motor control (cerebral pattern I) appeared invariably in placebo and verum conditions. In contrast, the other network, attributed to diminished motor control due to distracting mental processing (cerebral pattern II), emerged less regularly and exhibited more variability. Second‐level PCAs of both conditions confirmed the findings of the initial analysis. Specifically, it validated the dominant and invariable expression of cerebral pattern I after application of a single dose of escitalopram. Dynamic causal modeling confirmed enhanced motor output as a result of a significantly increased connectivity between primary motor cortex and dorsal premotor cortex.ConclusionThis pilot study suggests the promise of stimulation by a specific serotonin reuptake inhibitor in regard to recovery and preservation of motor control after stroke.

show abstract

“…When the methods developed using LC‐MS/MS in studies of S‐CT bioequivalence and TDM analysis and the method validated in our studies are compared, it has been determined that the sample preparation period or molecular type analysed is different from the literature. For example, Ansermot et al (2009) reported that the sample preparation procedure was performed by solid phase extraction (SPE) in the method developed for the TDM analysis of SSRI group drugs in plasma. Furthermore, in the same study, it was observed that S‐DDCT was not analysed in the developed method.…”

Section: Discussionmentioning

confidence: 99%

Quantitation of escitalopram and its metabolites by liquid chromatography‐tandem mass spectrometry in psychiatric patients: New metabolic ratio establishment

Canbolat

Erinç

Evrensel

et al. 2018

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Therapeutic drug monitoring (TDM) is used to determine the concentration of drug in plasma/serum to adjust the dose of the therapeutic drug. Selective and sensitive analytical methods are used to determine drug and metabolite levels for the successful application of TDM. The aim of the study was to develop and validate using LC-MS/MS to analyse quantitative assay of escitalopram (S-CT) and metabolites in human plasma samples. In order to provide a convenient and safe treatment dose, it was aimed to determine the levels of S-CT and its metabolites in the patients' plasma. A new method with short sample preparation and analysis time was developed and validated using LC-MS/MS to analyse quantitative assay of S-CT and its metabolites in plasma. Also, plasma samples of 30 patients using 20 mg S-CT between the ages of 18 and 65 years were analysed by the validated method. The mean values of S-CT, demethyl escitalopram and didemethyl escitalopram in plasma of patients were 27.59, 85.52 and 44.30 ng/mL, respectively. At the end of the analysis, the metabolic ratio of S-CT and metabolites was calculated. It is considered that the method for the quantitative analysis of S-CT and its metabolites in human plasma samples may contribute to the literature on account of its sensitive and easy application. Additionally, the use of our data by physicians will contribute to the effective drug treatment for their patients who take S-CT.

show abstract

Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography–electrospray mass spectrometry for therapeutic drug monitoring

Cited by 43 publications

References 46 publications

Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment

Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment

The effect of a single dose of escitalopram on sensorimotor networks

Quantitation of escitalopram and its metabolites by liquid chromatography‐tandem mass spectrometry in psychiatric patients: New metabolic ratio establishment

Contact Info

Product

Resources

About